Display options
Cite
van Dijk B, Potier E, Licht R, et al. The effect of a cyclooxygenase 2 inhibitor on early degenerated human nucleus pulposus explants. Global Spine J. 2013;4(1):33-40doi: 10.1055/s-0033-1359724.
van Dijk, B., Potier, E., Licht, R., Creemers, L., & Ito, K. (2014). The effect of a cyclooxygenase 2 inhibitor on early degenerated human nucleus pulposus explants. Global spine journal, 4(1), 33-40. https://doi.org/10.1055/s-0033-1359724
van Dijk, Bart, et al. "The effect of a cyclooxygenase 2 inhibitor on early degenerated human nucleus pulposus explants." Global spine journal vol. 4,1 (2014): 33-40. doi: https://doi.org/10.1055/s-0033-1359724
van Dijk B, Potier E, Licht R, Creemers L, Ito K. The effect of a cyclooxygenase 2 inhibitor on early degenerated human nucleus pulposus explants. Global Spine J. 2014 Feb;4(1):33-40. doi: 10.1055/s-0033-1359724. Epub 2013 Oct 23. PMID: 24494179; PMCID: PMC3908972.
Copy Download .nbib Format: NLM
Share it on

Global Spine J. 2014 Feb;4(1):33-40. doi: 10.1055/s-0033-1359724. Epub 2013 Oct 23.

The effect of a cyclooxygenase 2 inhibitor on early degenerated human nucleus pulposus explants.

Global spine journal

Bart van Dijk, Esther Potier, Ruud Licht, Laura Creemers, Keita Ito

Affiliations

  1. Orthopaedic Biomechanics, Department of Biomedical Engineering, Eindhoven University of Technology, Eindhoven, The Netherlands.
  2. Department of Orthopedics, University Medical Center Utrecht, Utrecht, The Netherlands.

PMID: 24494179 PMCID: PMC3908972 DOI: 10.1055/s-0033-1359724

Abstract

Study Design Preclinical in vitro culture of human degenerated nucleus pulposus (NP) tissue. Objective Cyclooxygenase 2 inhibitors (e.g., celecoxib) inhibit prostaglandin E2 (PGE2) production, and they have been shown to upregulate regeneration of articular cartilage. In this study, we developed an explant culture system for use with human tissue and tested the potential of celecoxib. Methods NP explants were cultured with or without 1 μM of celecoxib and were analyzed at days 0 and 7 for biochemical content (water, sulfated glycosaminoglycans, hydroxyproline, and DNA), gene expression (for disk matrix anabolic and catabolic markers), and PGE2 content. Results Water and biochemical contents as well as gene expression remained close to native values after 1 week of culture. PGE2 levels were not increased in freshly harvested human NP tissue and thus were not reduced in treated tissues. Although no anabolic effects were observed at the dosage and culture duration used, no detrimental effects were observed and some specimens did respond by lowering PGE2. Conclusions Human degenerated NP explants were successfully cultured in a close to in vivo environment for 1 week. Further research, especially dosage-response studies, is needed to understand the role of PGE2 in low back pain and the potential of celecoxib to treat painful disks.

Keywords: cyclooxygenase 2 inhibitor; explant culture; inflammation; intervertebral disk degeneration; regenerative therapy

References

  1. Spine (Phila Pa 1976). 2002 Oct 15;27(20):2212-9 - PubMed
  2. J Manipulative Physiol Ther. 2004 May;27(4):238-44 - PubMed
  3. Int Orthop. 1997;21(3):172-5 - PubMed
  4. Anal Biochem. 1980 Jul 1;105(2):424-9 - PubMed
  5. Arthritis Res Ther. 2003;5(3):120-30 - PubMed
  6. J Pathol. 2004 Sep;204(1):47-54 - PubMed
  7. Acta Orthop Scand. 1969;40(1):23-42 - PubMed
  8. Tissue Eng Part C Methods. 2011 Nov;17(11):1089-96 - PubMed
  9. Clin Biomech (Bristol, Avon). 2010 Dec;25(10):961-71 - PubMed
  10. Eur Cell Mater. 2011 Dec 19;22:420-36; discussion 436-7 - PubMed
  11. J Immunol. 2008 Oct 1;181(7):5082-8 - PubMed
  12. Spine J. 2005 Nov-Dec;5(6 Suppl):260S-266S - PubMed
  13. J Bone Joint Surg Br. 2002 Mar;84(2):196-201 - PubMed
  14. Spine (Phila Pa 1976). 2005 Jan 1;30(1):44-53; discussion 54 - PubMed
  15. Spine (Phila Pa 1976). 1990 May;15(5):411-5 - PubMed
  16. Connect Tissue Res. 1982;9(4):247-8 - PubMed
  17. Eur Spine J. 2008 Dec;17 Suppl 4:480-91 - PubMed
  18. Spine (Phila Pa 1976). 2008 Feb 15;33(4):356-65 - PubMed
  19. J Clin Invest. 1996 Aug 15;98(4):996-1003 - PubMed
  20. Arthritis Res Ther. 2005;7(4):R732-45 - PubMed
  21. Tissue Eng Part B Rev. 2010 Feb;16(1):147-58 - PubMed
  22. Arthritis Res Ther. 2006;8(1):R2 - PubMed
  23. Magn Reson Imaging. 2004 Sep;22(7):963-72 - PubMed
  24. J Biomech. 1999 Apr;32(4):401-8 - PubMed
  25. Eur Spine J. 2002 Aug;11(4):308-20 - PubMed
  26. Osteoarthritis Cartilage. 2003 Oct;11(10):747-55 - PubMed
  27. J Orthop Res. 2010 Oct;28(10):1259-66 - PubMed
  28. Spine (Phila Pa 1976). 1996 Jul 15;21(14):1653-5; discussion 1655-6 - PubMed
  29. Spine J. 2008 Jan-Feb;8(1):8-20 - PubMed
  30. Spine J. 2013 Apr;13(4):454-63 - PubMed
  31. Rheumatol Int. 2008 Jun;28(8):727-36 - PubMed
  32. Spine J. 2004 Nov-Dec;4(6 Suppl):330S-340S - PubMed
  33. Eur Spine J. 2008 Jan;17(1):2-19 - PubMed
  34. Spine (Phila Pa 1976). 2009 May 20;34(12):1264-71 - PubMed
  35. Spine J. 2005 Nov-Dec;5(6 Suppl):267S-279S - PubMed
  36. Anal Biochem. 1979 Nov 15;100(1):188-97 - PubMed
  37. Spine (Phila Pa 1976). 1996 Feb 1;21(3):271-7 - PubMed
  38. Spine (Phila Pa 1976). 2002 Dec 1;27(23):2631-44 - PubMed
  39. Osteoarthritis Cartilage. 2005 Jun;13(6):519-26 - PubMed
  40. Ann Rheum Dis. 2011 Oct;70(10):1740-5 - PubMed
  41. Spine (Phila Pa 1976). 2003 Dec 15;28(24):2685-93 - PubMed
  42. Arthritis Res Ther. 2011;13(5):239 - PubMed

Publication Types